Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. It has shown encouraging clinical e...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
